Analyses using immunofluorescence and fluorescence-activated cell technology confirmed that CD47 is widely expressed in most urothelial carcinoma cells, and CD44+ CSCs have higher CD47 expression level compared to subset of CD44−tumor cells. This evidence concerns the gene CD44 and urothelial carcinoma.